ABSTRACT
In this study, solid lipid nanoparticles containing Eugenia caryophyllata essential oil (SLN-EO) were prepared by high-shear homogenization and ultrasound methods, and used to eradicate pathogens. SLN formulations were evaluated for their size, zeta potential and encapsulation efficacy (EE). The morphological and thermal properties of the formulations were analysed by transmission electron microscopy (TEM) and differential scanning calorimetry methods. The lead formulations were chosen and tested with minimum inhibitory concentration (MIC), MBC and time-kill methods to investigate the antimicrobial activity against Salmonella typhi, Pseudomonas aeruginosa, Staphylococcus aureus and Candida albicans. The particle size of three final formulations were 397 ± 10·1, 786·9 ± 11 and 506·4 ± 22 nm respectively. The zeta potential of all formulations was negative values. The size of the formulations was slightly increased during 3 months storage at 25°C. The TEM imaging showed that formulation had spherical shape. The EE of EO was estimated approximately 70%. MIC and MCC values of SLN-EO were lower than those of the oil alone. The time-kill studies showed that SLN-EO was either equivalent to or better than EO (P-value <0·05). The results of this study highlighted the effectiveness of SLN formulations against human pathogens. SIGNIFICANCE AND IMPACT OF THE STUDY: Microbial resistance to antibiotics is a major problem in the treatment of diseases. Therefore, overcoming antimicrobial resistance is an urgent need. Drug delivery via nanoparticles and applying natural products are promising approaches to reduce microbial resistance. This study is designed to evaluate the antimicrobial activity of solid lipid nanoparticles (SLN) containing Eugenia caryophyllata essential oil (EO) against human pathogens. The results indicated that the antimicrobial activity of EO was remarkably enhanced when encapsulated in SLN.
Subject(s)
Anti-Infective Agents/pharmacology , Candida albicans/drug effects , Drug Delivery Systems/methods , Lipids/pharmacology , Oils, Volatile/pharmacology , Pseudomonas aeruginosa/drug effects , Salmonella typhi/drug effects , Staphylococcus aureus/drug effects , Calorimetry, Differential Scanning , Humans , Lipids/chemistry , Microbial Sensitivity Tests , Microscopy, Electron, Transmission , Nanoparticles/chemistry , Particle Size , Syzygium/chemistryABSTRACT
Galbanic acid, a sesquiterpene coumarin from Ferula szowitsiana, and conferol, another sesquiterpene coumarin from F. badrakema, were evaluated for their effects on the reversal of multi-drug resistance in clinical isolates of Staphylococcus aureus and Escherichia coli, respectively. Neither galbanic acid (up to 1000 µg/ml) nor conferol (up to 400 µg/ml) by itself shows any antibacterial activities against tested strains. The minimum inhibitory concentrations (MICs) of ciprofloxacin and tetracycline were determined using macrodilution technique in the presence and absence of sub-inhibitory concentrations of galbanic acid (31.25-1000 µg/ml) or conferol (50-400 µg/ml), however they caused no change in MICs of the antibiotics. Galbanic acid did not show any inhibitory effect on efflux phenomenon of E. coli. This can be related to the outer membrane of gram-negative bacteria which is impermeable to lipophilic compounds or another mechanism rather than efflux responsible for resistance in tested E. coli strains. An inhibitory effect of conferol on the efflux was compared with verapamil as a positive control. Because efflux is the only known mechanism of resistance to ethidium bromide (model efflux substrate) and verapamil reduced MIC of ethidium bromide, efflux mechanism can be considered as one of the resistance mechanisms in tested S. aureus strains. Conferol, however, did not enhance the antibiotic efficacy mediated by inhibiting efflux pumps in bacteria.
